Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Duloxetine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 known ✓ | P31645 | 14/20 | 1.00 |
| ▸ | SLC6A2 known ✓ | P23975 | 13/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 9/20 | 1.00 |
| ▸ | MLNR | O43193 | 1/20 | 1.00 |
| ▸ | CACNA1F | O60840 | 1/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | ADRB1 | P08588 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | HTR1A | P08908 | 1/20 | 1.00 |
| ▸ | GAA | P10253 | 1/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 1/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 1.00 |
| ▸ | DRD2 | P14416 | 1/20 | 1.00 |
| ▸ | KCNE1 | P15382 | 1/20 | 1.00 |
| ▸ | ADRA2B | P18089 | 1/20 | 1.00 |
| ▸ | ADRA2C | P18825 | 1/20 | 1.00 |
| ▸ | HTR2A | P28223 | 1/20 | 1.00 |
| ▸ | HTR2C | P28335 | 1/20 | 1.00 |
| ▸ | MC4R | P32245 | 1/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Duloxetine SCHEMBL10036575 | 1.00 | SLC6A4 (1.00) | SLC6A4SLC6A2SLC6A3MLNRCACNA1F | |
| (R)-Duloxetine SCHEMBL1200511 | 1.00 | SLC6A4 (1.00) | SLC6A4SLC6A2SLC6A3MLNRCACNA1F | |
| Duloxetine SCHEMBL29355040 | 1.00 | SLC6A4 (1.00) | SLC6A4SLC6A2SLC6A3MLNRCACNA1F | |
| (R)-Duloxetine SCHEMBL30003730 | 1.00 | SLC6A4 (1.00) | SLC6A4SLC6A2SLC6A3MLNRCACNA1F | |
| Duloxetine SCHEMBL30197067 | 1.00 | SLC6A4 (1.00) | SLC6A4SLC6A2SLC6A3MLNRCACNA1F | |
| Duloxetine SCHEMBL3803 | 1.00 | SLC6A4 (1.00) | SLC6A4SLC6A2SLC6A3MLNRCACNA1F | |
| Duloxetine SCHEMBL8291 | 1.00 | SLC6A4 (1.00) | SLC6A4SLC6A2SLC6A3MLNRCACNA1F | |
| Duloxetine SCHEMBL2384759 | 0.99 | SLC6A2 (0.98) | SLC6A4SLC6A2SLC6A3MLNRCACNA1F | |
| (R)-Duloxetine SCHEMBL3901869 | 0.99 | SLC6A2 (0.98) | SLC6A4SLC6A2SLC6A3MLNRCACNA1F | |
| Duloxetine SCHEMBL647773 | 0.99 | SLC6A2 (0.98) | SLC6A4SLC6A2SLC6A3MLNRCACNA1F |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200147041-A1 | PAROXYSMAL EXTREME PAIN DISORDER TREATMENT | Convergence Pharmaceuticals Limited (GB) | 2020-05-14 | — | — | US | disclosed |
| US-20170290802-A1 | Novel Small Fibre Neuropathy Treatment | Convergence Pharmaceuticals Limited (GB) | 2017-10-12 | — | — | US | disclosed |
| EP-2906208-A1 | THERAPEUTIC TREATMENT | Sears, Douglas (US) | 2015-08-19 | — | — | EP | disclosed |
| CN-102698798-A | Porous iron-based catalyst and application thereof | UNIV WENZHOU | 2012-10-03 | — | — | CN | disclosed |
| WO-2010036965-A2 | GENETIC MARKERS OF SCHIZOPHRENIA ENDOPHENOTYPES | SUREGENE LLC (US) | 2010-04-01 | — | — | WO | disclosed |
| EP-1670427-A4 | METHODS AND REAGENTS FOR THE TREATMENT OF IMMUNOINFLAMMATORY DISORDERS | COMBINATORX INC (US) | 2009-01-07 | — | — | EP | disclosed |
| US-20080207601-A1 | Methods of and Compositions For the Prevention of Anxiety, Substance Abuse, and Dependence | HYTHIAM , INC. (US) | 2008-08-28 | — | — | US | disclosed |
| EP-1680121-A4 | METHODS AND REAGENTS FOR THE TREATMENT OF IMMUNOINFLAMMATORY DISORDERS | COMBINATORX INC (US) | 2007-12-26 | — | — | EP | disclosed |
| EP-1868593-A2 | IMPROVED METHODS OF AND COMPOSITIONS FOR THE PREVENTION OF ANXIETY, SUBSTANCE ABUSE, AND DEPENDENCE | Hythiam, Inc. (US) | 2007-12-26 | — | — | EP | disclosed |
| CN-1988896-A | Use of compounds active on the sigma receptor for the treatment of mechanical allodynia | ESTEVE LABOR DR (ES) | 2007-06-27 | — | — | CN | disclosed |
| WO-2006110642-A2 | IMPROVED METHODS OF AND COMPOSITIONS FOR THE PREVENTION OF ANXIETY, SUBSTANCE ABUSE, AND DEPENDENCE | HYTHIAM, INC. (US) | 2006-10-19 | — | — | WO | disclosed |
| EP-1680121-A2 | METHODS AND REAGENTS FOR THE TREATMENT OF IMMUNOINFLAMMATORY DISORDERS | CombinatoRx, Incorporated (US) | 2006-07-19 | — | — | EP | disclosed |
| EP-1670427-A2 | METHODS AND REAGENTS FOR THE TREATMENT OF IMMUNOINFLAMMATORY DISORDERS | CombinatoRx, Incorporated (US) | 2006-06-21 | — | — | EP | disclosed |
| EP-1599212-A4 | COMBINATION THERAPY FOR THE TREATMENT OF IMMUNOINFLAMMATORY DISORDERS | COMBINATORX INC (US) | 2006-02-08 | — | — | EP | disclosed |
| EP-1599212-A2 | COMBINATION THERAPY FOR THE TREATMENT OF IMMUNOINFLAMMATORY DISORDERS | Combinatorx, Incorporated (US) | 2005-11-30 | — | — | EP | disclosed |
| WO-2005079284-A2 | METHODS AND REAGENTS FOR THE TREATMENT OF DISEASES AND DISORDERS ASSOCIATED WITH INCREASED LEVELS OF PROINFLAMMATORY CYTOKINES | COMBINATORX, INCORPORATED (US) | 2005-09-01 | — | — | WO | disclosed |
| WO-2005037203-A2 | METHODS AND REAGENTS FOR THE TREATMENT OF IMMUNOINFLAMMATORY DISORDERS | COMBINATORX, INCORPORATED (US) | 2005-04-28 | — | — | WO | disclosed |
| WO-2005027839-A2 | METHODS AND REAGENTS FOR THE TREATMENT OF IMMUNOINFLAMMATORY DISORDERS | COMBINATORX, INCORPORATED (US) | 2005-03-31 | — | — | WO | disclosed |
| WO-2004073614-A2 | COMBINATION THERAPY FOR THE TREATMENT OF IMMUNOINFLAMMATORY DISORDERS | COMBINATORX, INCORPORATED (US) | 2004-09-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170290802-A1 | Novel Small Fibre Neuropathy Treatment | PMP22, PRPH, SMN1; SMN2 | SLC6A4 107/4885SLC6A2 74/4885SLC6A3 153/4885 |
| US-20200147041-A1 | PAROXYSMAL EXTREME PAIN DISORDER TREATMENT | PEPD, FAP, PREP | SLC6A4 67/4885SLC6A2 151/4885SLC6A3 58/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.